Regression of Post-Essential Thrombocythemia Myelofibrosis with Intermittent Hydroxyurea Therapy: A Case Report
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
We describe a patient with post-essential thrombocythemia myelofibrosis treated with intermittent hydroxyurea (Hu) therapy (20mg/Kg, given as a single dose, thrice weekly), achieving sustained disease control and regression of bone marrow fibrosis; and, discuss the efficacy of and rationale for use of intermittent Hu therapy in patients with myeloproliferative neoplasms, including those deemed to be Hu-resistant or intolerant on the commonly used continuous therapy.